Savara merilis presentasi korporasi tentang penyakit paru langka autoimmune PAP dan kandidat terapi inhalasi MOLBREEVI

Reuters2026/08/11 20:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Savara Inc. menyoroti kandidat utama MOLBREEVI (molgramostim inhalation solution) untuk autoimmune PAP, penyakit paru langka tanpa obat disetujui di AS atau Eropa.
Perusahaan mencantumkan tanggal PDUFA BLA pada 22 November 2026 untuk MOLBREEVI.
Uji fase 3 IMPALA-2 mencapai endpoint primer: perubahan DLCO% pada minggu 24 unggul atas plasebo, p=0,0007.
Efek berlanjut pada minggu 48: DLCO% p=0,0008; SGRQ total minggu 24 p=0,0072; kapasitas olahraga minggu 48 p=0,0234.
Keamanan ditampilkan sebagai ditoleransi baik; penghentian terapi 3%; 160 peserta masuk periode open-label, 100% dari penyelesai double-blind.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Savara merilis presentasi korporasi tentang penyakit paru langka autoimmune PAP dan kandidat terapi inhalasi MOLBREEVI

You may also like

Crypto prices